Co-Authors
This is a "connection" page, showing publications co-authored by JOHN KIRKWOOD and JEFFREY E GERSHENWALD.
Connection Strength
0.839
-
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
Score: 0.159
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.057
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.
Score: 0.056
-
Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol. 2022 Sep; 29(9):5948-5956.
Score: 0.055
-
The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
Score: 0.050
-
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
Score: 0.049
-
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
Score: 0.049
-
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
Score: 0.046
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
Score: 0.045
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.041
-
The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.
Score: 0.036
-
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
Score: 0.032
-
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
Score: 0.031
-
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
Score: 0.030
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.028
-
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
Score: 0.024
-
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
Score: 0.023
-
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
Score: 0.016
-
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
Score: 0.014